BioSpace News Archive

As consumer awareness for vitamins and supplements continue to proliferate, vitamin K market size is expected to grow considerably.

Bioelectronica Corporation (“Bioelectronica”) today announced the closing of an investment by Proxima Ventures and Co-win Ventures to advance the company’s innovations in digital biochemistry, from novel assay development to scalable electrofluidics.

World reknowned medical and clinical experts to guide Genprex’ novel gene therapy clinical development programs in cancer and diabetes, including its two upcoming clinical trials in lung cancer

T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced that the Company plans to participate in the upcoming BTIG Virtual MedTech, Digital Health, Life Science & Diagnostics Tools Conference.

Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it has commenced an underwritten public offering of up to $100 million of its American Depositary Shares (“ADSs”), each ADS representing one ordinary share.

Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) (“CBMG” or the “Company”) announced that, at the Company’s special meeting of stockholders held today, its stockholders approved the proposal to adopt the previously announced Agreement and Plan of Merger, dated as of August 11, 2020

DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the additions of Dr. Lisa Beck and Dr. George Han to its Scientific Advisory Board (“SAB”).

Zomedica Corp. announced that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC under which the underwriter has agreed to purchase on a firm commitment basis 13,157,895 common shares of Zomedica, at a price to the public of $1.90 per share, less underwriting discounts and commissions.

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the final analysis of the Phase 3 TITAN study, which demonstrated the continued statistically significant benefit of the addition of ERLEADA® (apalutamide) to androgen deprivation therapy (ADT) in overall survival (OS) in patients with metastatic castration-sensitive prostate cancer (mCSPC

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the randomized, double-blind, placebo-controlled Phase 3 ACIS study, which met the primary endpoint of radiographic progression-free survival (rPFS)